As we have previously observed, innovation in health care, particularly on the product side, is heavily dependent on venture funding, and on the cycle of successful exits that generates capital for new investments. 2014 was an excellent year for venture finance, according to recently released stats from the National Venture Capital Association. (NVCA Reports) In the fourth quarter, venture funds raised $5.6 billion and for all of 2014, $29.8 billion was raised, up 69% from 2013. There were 96 new funds and 158 follow-on ones. On the exit side, there were 27 venture-backed IPOs during the fourth quarter that raised $4.4 billion and for the full year there were 115 such offerings which garnered $15.3 billion. The number of IPOs was up from 81 in 2013 and the amount raised rose from $ 11.1 billion. 16 of these IPOs in the fourth quarter were in health care, raising $1.7 billion. There were also 95 venture-backed M & A exits, of which 29 reported an aggregate deal value of $26.4 billion, although this is sharply skewed by Facebook’s absurd $19.5 billion purchase of Whatsapp. The full year saw 455 acquisitions of venture-backed firms, with 132 reporting a total value of $46 billion. The comparable 2013 numbers were 393 deals with 95 reporting transaction values of $16.9 billion. Health care in the fourth quarter accounted for 10 of these deals, with 7 of them reporting a total value of $2.7 billion. Of reported deals in the fourth quarter, 5 of 29 returned less than was invested, 6 were at 1-4X, 11 were at 4-10X and 7 were over ten times investment. The financing and exit markets appear to be in good health heading into 2015.
Venture Funding and Exits in the Fourth Quarter and 2014
By Kevin RocheJanuary 15, 2015Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 27, 2023
Why You Can’t Trust People Who Make Up Stuff About Vax Safety
A couple of studies offer a far better explanation for heart issues in athletes and…
March 25, 2023
Coronamonomania Lives Forever, Part 201
Tired of March Madness? A boringly refreshing dip into some CV-19 research summaries is recommended.
March 24, 2023
The CDC Is a Font of Methodological and Statistical Error
Several times in the last three years I and others have pointed out serious flaws…